verlukast and Neoplasms

verlukast has been researched along with Neoplasms* in 4 studies

Other Studies

4 other study(ies) available for verlukast and Neoplasms

ArticleYear
Characterization of the intestinal absorption of morroniside from Cornus officinalis Sieb. et Zucc via a Caco-2 cell monolayer model.
    PloS one, 2020, Volume: 15, Issue:5

    Morroniside is a biologically active polyphenol found in Cornus officinalis Sieb. et Zucc (CO) that exhibits a broad spectrum of pharmacological activities, such as protecting nerves, and preventing diabetic liver damage and renal damage. However, little data are available regarding the mechanism of its intestinal absorption. Here, an in vitro human intestinal epithelial cell model of cultured Caco-2 cells was applied to study the absorption and transport of morroniside. The effects of donor concentration, pH and inhibitors were investigated. The bidirectional permeability of morroniside from the apical (AP) to the basolateral (BL) side and in the reverse direction was studied. When administered at three tested concentrations (5, 25 and 100 μM), the apparent permeability coefficient (Papp) values in the AP-to-BL direction ranged from 1.59 × 10-6 to 2.66 × 10-6 cm/s. In the reverse direction, BL-to-AP, the value was ranged from 2.67 × 10-6 to 4.10 × 10-6 cm/s. The data indicated that morroniside transport was pH-dependent. The permeability of morroniside was affected by treatment with various inhibitors, such as multidrug resistance protein inhibitors MK571 and indomethacin, as well as the breast cancer resistance protein inhibitor apigenin. The mechanisms of the intestinal absorption of morroniside may involve multiple transport pathways, such as the passive diffusion and efflux protein-mediated active transport especially involving multidrug resistance protein 2 and breast cancer resistance protein. After the addition of CO, the Papp values in the AP-to-BL direction increased significantly, therefore, it can be assumed that some ingredients in the CO promote morroniside absorption in the small intestine.

    Topics: ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Sub-Family B Member 4; Caco-2 Cells; Cell Proliferation; Cornus; Epithelial Cells; Gene Expression Regulation, Neoplastic; Glycosides; Humans; Indomethacin; Intestinal Absorption; Neoplasm Proteins; Neoplasms; Permeability; Propionates; Quinolines

2020
Different Efflux Transporter Affinity and Metabolism of
    Pharmaceutical research, 2018, Nov-29, Volume: 36, Issue:1

    Little is known about the affinity and stability of. In vesicles,

    Topics: Animals; Cell Line, Tumor; Drug Monitoring; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Stability; Female; Humans; Liver; Mice, SCID; Molecular Imaging; Multidrug Resistance-Associated Proteins; Neoplasms; Organophosphorus Compounds; Organotechnetium Compounds; Propionates; Quinolines; Radiopharmaceuticals; Time Factors; Verapamil; Xenograft Model Antitumor Assays

2018
Pharmacogenomics approach reveals MRP1 (ABCC1)-mediated resistance to geldanamycins.
    Pharmaceutical research, 2009, Volume: 26, Issue:4

    Geldanamycin and its analogues belong to a new class of anticancer agents that inhibit the molecular chaperone heat shock protein 90. We hypothesized that membrane transporters expressed on tumor cells may contribute at least in part to cellular sensitivity to these agents. The purpose of this study is to identify novel transporters as determinant for sensitivity and resistance to geldanamycins.. To facilitate a systematic study of chemosensitivity across multiple geldanamycin analogues, we correlated mRNA expression profiles of majority of transporters with anticancer drug activities in 60 human tumor cell lines (NCI-60). We subsequently validated the gene-drug correlations using cytotoxicity and transport assays.. The GA analogues displayed negative correlations with mRNA expression levels of the multidrug resistance protein 1 (MRP1, ABCC1). Suppressing MRP1 efflux using the inhibitor MK-571 and small interfering RNA in cell lines with intrinsic and acquired MRP1 overexpression (A549 and HL-60/ADR) and in cell lines stably transduced with MRP1 (MCF7/MRP1) increased intracellular drug accumulation and increased tumor cell sensitivity to geldanamycin analogues.. These results suggest that elevated expression of MRP1, like the alternative efflux transporter MDR1 (ABCB1, P-glycoprotein), can significantly influence tumor cell sensitivity to geldanamycins as a potential chemoresistance factor.

    Topics: Antineoplastic Agents; Benzoquinones; Biological Transport; Cell Proliferation; Cell Survival; Databases, Genetic; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; HL-60 Cells; Humans; Lactams, Macrocyclic; Multidrug Resistance-Associated Proteins; Neoplasms; Oligonucleotide Array Sequence Analysis; Pharmacogenetics; Propionates; Quinolines; Reproducibility of Results; RNA Interference; RNA, Messenger; RNA, Small Interfering; Transfection; Up-Regulation

2009
Montelukast is a potent and durable inhibitor of multidrug resistance protein 2-mediated efflux of taxol and saquinavir.
    Biological & pharmaceutical bulletin, 2009, Volume: 32, Issue:12

    The ATP binding cassette (ABC)-transporters are energy dependent efflux pumps which regulate the pharmacokinetics of both anti-cancer chemotherapeutic agents, e.g. taxol, and of human immunodeficiency virus-1 (HIV-1) protease inhibitors (HPIs), e.g. saquinavir. Increased expression of several ABC-transporters, especially P-glycoprotein (P-gp) and multidrug resistance protein 2 (MRP2), are observed in multidrug resistant (MDR) tumor cells and on HIV-1 infected lymphocytes. In addition, due to their apical expression on vascular endothelial barriers, both P-gp and MRP2 are of crucial importance towards dictating drug access into sequestered tissues. However, although a number of P-gp inhibitors are currently in clinical trials, possible inhibitors of MRP2 are not being thoroughly investigated. The experimental leukotriene receptor antagonist (LTRA), MK-571 is known to be a potent inhibitor of MRP transporters. Using the MRP2 over-expressing Madin-Darby canine kidney cell line, MDCKII-MRP2, we evaluated whether the clinically approved LTRAs, e.g. montelukast (Singulair) and zafirlukast (Accolate), can similarly suppress MRP2-mediated efflux. We compared the efficacy of increasing concentrations (20-100 microM) of MK-571, montelukast, and zafirlukast, in suppressing the efflux of calcein-AM, a fluorescent MRP substrate, and the radiolabeled [(3)H-] drugs, taxol and saquinavir. Montelukast was the most potent inhibitor (p<0.01) of MRP2-mediated efflux of all three substrates. Montelukast also increased (p<0.01) the duration of intracellular retention of both taxol and saquinavir. More than 50% of the drugs were retained in cells even after 90 min post removal of montelukast from the medium. Our findings implicate that montelukast, a relatively safe anti-asthmatic agent, may be used as an adjunct therapy to suppress the efflux of taxol and saquinavir from MRP2 overexpressing cells.

    Topics: Acetates; Animals; Anti-Asthmatic Agents; Antineoplastic Agents, Phytogenic; Biological Transport; Cell Line; Chemotherapy, Adjuvant; Cyclopropanes; Dogs; Drug Resistance, Neoplasm; Drug Resistance, Viral; Fluoresceins; HIV Infections; HIV Protease Inhibitors; Indoles; Leukotriene Antagonists; Multidrug Resistance-Associated Proteins; Neoplasms; Paclitaxel; Phenylcarbamates; Propionates; Quinolines; Saquinavir; Sulfides; Sulfonamides; Time Factors; Tosyl Compounds

2009